[Off-Label Repurposed Use Of Tirzepatide In Non-Diabetic Patients With Metabolic Syndrome] by Doctor Pete

Abstract

Metabolic syndrome is a cluster of conditions that occur together, increasing the risk of heart disease, stroke, and type 2 diabetes. These conditions include increased blood pressure, high blood sugar, excess body fat around the waist, and abnormal cholesterol or triglyceride levels. Tirzepatide, a drug initially approved for the treatment of type 2 diabetes, has shown promising results in managing metabolic syndrome in non-diabetic patients. This paper aims to explore the off-label repurposed use of Tirzepatide in non-diabetic patients with metabolic syndrome.

Introduction

Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist that has been approved for the treatment of type 2 diabetes¹. Recent studies have suggested that Tirzepatide may also be beneficial in the management of metabolic syndrome¹.

Methodology

The SURPASS clinical trial program for type 2 diabetes demonstrated that Tirzepatide led to greater improvements in glycemic control, body weight reduction, and other cardiometabolic risk factors compared to placebo, subcutaneous semaglutide 1 mg, insulin degludec, and insulin glargine¹. A post hoc analysis from this program assessed the effect of Tirzepatide use on the prevalence of patients meeting the criteria for metabolic syndrome¹.

Results

The SURPASS program revealed that the prevalence of patients meeting the criteria for metabolic syndrome at baseline was 67–88% across treatment groups. This prevalence reduced to 38–64% with Tirzepatide versus 64–82% with comparators¹. Reductions in the prevalence of patients meeting the criteria for metabolic syndrome were significantly greater with all Tirzepatide doses versus placebo, semaglutide 1 mg, insulin glargine, and insulin degludec¹.

Discussion

The results suggest that Tirzepatide could be a potential therapeutic option for non-diabetic patients with metabolic syndrome. However, more extensive studies are needed to confirm these findings and to explore the long-term effects and safety of Tirzepatide in this population.

Conclusion

Tirzepatide has shown promising results in the management of metabolic syndrome in non-diabetic patients. Further research is warranted to establish the safety and efficacy of Tirzepatide in this new patient population.

References

¹: “Reduction of prevalence of patients meeting the criteria for metabolic syndrome with tirzepatide: a post hoc analysis from the SURPASS Clinical Trial Program”, Cardiovascular Diabetology, 2024

Source: Conversation with Bing, 15/05/2024
(1) Reduction of prevalence of patients meeting the criteria for metabolic …. https://cardiab.biomedcentral.com/articles/10.1186/s12933-024-02147-9.

Metabolic Syndrome Triage app by Doctor Pete:
https://drpetedo.code.blog/metabolic/

Cc/ mayor Carlos Moedas
Dr. Dr. Shelly MD